Nuvig
22 employees on LinkedIn · 7 known investors
Find your way into Nuvig
542 people in our graph share verified history with the Nuvig team — schools, employers, funds. One of them is your warm intro.
Mike Volpiunlockedknows Pamela Conley · together at Stanford University (overlapped)
×11knows the team · via Stanford University
Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation. The company targets patients with chronic inflammatory and autoimmune conditions.
Founders & leadership
PC
Pamela ConleyinChief Scientific Officer and Co-founderPamela Conley holds a Ph.D. and has more than 25 years of experience in drug discovery and development, with expertise in small molecule and biologic therapeutics across cardiovascular disease, inflammation, and hematologic malignancies. She has led target identification and validation, clinical development, and regulatory submissions for multiple investigational new drugs.
Investors · 7
.jpeg){kind=logo}
Funding
SEC filings, press & company announcements$161M disclosed across 1 round · 2024
- $161MraisedDec 2024 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Nuvig do?
- Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation. The company targets patients with chronic inflammatory and autoimmune conditions.
- Who founded Nuvig?
- Nuvig was founded by Pamela Conley.
- Who are Nuvig's investors?
- Nuvig's investors include B Capital Group, B4 Capital, Global BioAccess Fund, Mission Biocapital, Sanofi Ventures, Digitalis Ventures, Norwest Venture Partners.
- How much funding has Nuvig raised?
- Nuvig has disclosed $161M raised across 1 round.